Press Release Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma 4 hours ago
Press Release Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board Aug 10
Press Release Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Jul 27